Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma

NCT05161143 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Donafenib

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]